...
首页> 外文期刊>Urology >The effect of baseline testosterone on the efficacy of degarelix and leuprolide: Further insights from a 12-month, comparative, phase III study in prostate cancer patients
【24h】

The effect of baseline testosterone on the efficacy of degarelix and leuprolide: Further insights from a 12-month, comparative, phase III study in prostate cancer patients

机译:基线睾丸激素对地加瑞克和亮丙瑞林功效的影响:一项为期12个月的比较性III期前列腺癌研究的进一步见解

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Objective: To investigate the effects of baseline testosterone on testosterone control and prostate-specific antigen (PSA) suppression using data from a phase III trial (CS21) comparing degarelix and leuprolide in prostate cancer. Methods: In CS21, patients with histologically confirmed prostate cancer (all stages) were randomized to degarelix 240 mg for 1 month followed by monthly maintenance doses of 80 or 160 mg, or leuprolide 7.5 mg/month. Patients receiving leuprolide could receive antiandrogens for flare protection. Treatment effects on testosterone and PSA reduction, testosterone surge, and microsurges were investigated in 3 baseline testosterone subgroups: <3.5, 3.5-5.0, and >5.0 ng/mL. Data are presented for the groups receiving degarelix 240/80 mg (the approved dose) and leuprolide 7.5 mg. Results: Higher baseline testosterone delayed castration with both treatments. However, castrate testosterone levels and PSA suppression occurred more rapidly with degarelix irrespective of baseline testosterone. With leuprolide, the magnitude of testosterone surge and microsurges increased with increasing baseline testosterone. There was no overall correlation between baseline testosterone and initial PSA decrease in either treatment group, although PSA suppression tended to be slowest with leuprolide and fastest with degarelix in the high baseline testosterone subgroup. Conclusion: Patients with high baseline testosterone may have greater risk of tumor stimulation (clinical flare) and mini-flares during gonadotrophin-releasing hormone agonist treatment and so the need for flare protection with antiandrogens in these patients is obvious, especially in metastatic disease. Although higher baseline testosterone delays castration, castrate testosterone and PSA suppression occur more rapidly with degarelix, irrespective of baseline testosterone, without the need for flare protection.
机译:目的:使用III期试验(CS21)比较地加瑞克和亮丙瑞林在前列腺癌中的数据,研究基线睾丸激素对睾丸激素控制和前列腺特异性抗原(PSA)抑制的作用。方法:在CS21中,将经组织学确认为前列腺癌(所有阶段)的患者随机分配至degarelix 240 mg,治疗1个月,然后每月维持剂量80或160 mg,或亮丙瑞林7.5 mg /月。接受亮丙瑞林的患者可以接受抗雄激素以预防耀斑。在3个基线睾丸激素亚组中研究了对睾丸激素和PSA降低,睾丸激素激增和微创的治疗效果:<3.5、3.5-5.0和> 5.0 ng / mL。给出了接受地加瑞克240/80 mg(批准的剂量)和亮丙瑞林7.5 mg的组的数据。结果:两种治疗均导致较高的基线睾丸激素延迟去势。然而,无论基线睾丸激素水平如何,地加瑞克都会使去势睾丸激素水平和PSA抑制发生得更快。使用亮丙瑞林,睾丸激素激增和微搏的幅度随基线睾丸激素的增加而增加。在两个治疗组中,基线睾丸激素和初始PSA降低之间没有总体相关性,尽管在基线睾丸激素高的亚组中,使用亮丙瑞林的PSA抑制作用最慢,而使用degarelix的PSA抑制作用往往最快。结论:基线睾丸激素水平较高的患者在促性腺激素释放激素激动剂治疗期间可能具有更大的肿瘤刺激(临床耀斑)和微小耀斑风险,因此这些患者尤其是转移性疾病中,需要使用抗雄激素来保护耀斑的需求明显。尽管较高的基线睾丸激素会延迟去势,但无论使用哪种基线睾丸激素,地加瑞克都会更快地发生去势睾丸激素和PSA抑制,而无需眩光保护。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号